Trials / Completed
CompletedNCT02753088
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC "BIOCAD", Russia) and Copaxone®-Teva ("Teva Pharmaceutical Industries Limited", Israel) in Patients With Relapsing-remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCD-063 | |
| DRUG | Copaxone-Teva | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2016-04-27
- Last updated
- 2021-09-16
Source: ClinicalTrials.gov record NCT02753088. Inclusion in this directory is not an endorsement.